# Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

> **NCT06525675** · — · COMPLETED · sponsor: **MedSIR** · enrollment: 419 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Advanced Breast Cancer
- Luminal Breast Cancer
- HER2-negative Breast Cancer
- ER-positive Breast Cancer

## Interventions

- **DRUG:** Fulvestrant Injectable Product
- **DRUG:** Letrozole 2.5mg
- **DRUG:** Palbociclib 125mg

## Key facts

- **NCT ID:** NCT06525675
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-18
- **Primary completion:** 2024-05-26
- **Final completion:** 2024-09-02
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2024-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06525675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06525675, "Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06525675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*